Immunotherapy and Immunomodulation in Myeloproliferative Neoplasms

Results from a Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate, or High Risk, Relapsed/Refractory Myelofibrosis

(2020) Naveen Pemmaraju et al.   BLOOD

Baricitinib as potential treatment for 2019-nCoV acute respiratory disease

(2020) Peter Richardson et al.   LANCET

Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study

(2020) Heinz Gisslinger et al.   Lancet Haematology

Histone deacetylase inhibitors valproic acid and vorinostat enhance trastuzumab-mediated antibody-dependent cell-mediated phagocytosis

(2020) Johannes Laengle et al.   Journal for ImmunoTherapy of Cancer

Treating Leukemia in the Time of COVID-19

(2020) Shilpa Paul et al.   ACTA HAEMATOLOGICA

Expression of CD47 and CALR in myeloproliferative neoplasms and myelodysplastic syndrome: Potential new therapeutical targets.

(2020) Ciro Roberto Rinaldi et al.   JOURNAL OF CLINICAL ONCOLOGY

TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib

(2020) Dandan Wu et al.   JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION

COVID-19: consider cytokine storm syndromes and immunosuppression

(2020) Puja Mehta et al.   LANCET

Single-Cell Analyses Reveal Megakaryocyte-Biased Hematopoiesis in Myelofibrosis and Identify Mutant Clone-Specific Targets

(2020) Bethan Psaila et al.   MOLECULAR CELL

Finally, a Successful Randomized Trial for GVHD

(2020) Nelson Chao   NEW ENGLAND JOURNAL OF MEDICINE

Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease

(2020) Robert Zeiser et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immune Checkpoint Inhibitors in Acute Myeloid Leukemia: Novel Combinations and Therapeutic Targets

(2019) Maximilian Stahl et al.   Current Oncology Reports

Immune checkpoint-based therapy in myeloid malignancies: a promise yet to be fulfilled

(2019) Jan Philipp Bewersdorf et al.   Expert Review of Anticancer Therapy

SMAC mimetics as potential cancer therapeutics in myeloid malignancies

(2019) Prajwal Boddu et al.   BRITISH JOURNAL OF HAEMATOLOGY

Characteristics of patients with myeloproliferative neoplasms with lymphoma, with or without JAK inhibitor therapy

(2019) Naveen Pemmaraju et al.   BLOOD

JAK inhibitors and risk of B-cell lymphomas

(2019) Elisa Rumi et al.   BLOOD

Myeloablative conditioning using timed-sequential busulfan plus fludarabine in older patients with acute myeloid leukemia: long term results of a prospective phase II clinical trial

(2019) Rohtesh S. Mehta et al.   HAEMATOLOGICA

Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm

(2019) Naveen Pemmaraju et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immune Checkpoint Blockade Enhances Shared Neoantigen-Induced T Cell Immunity Directed against Mutated Calreticulin in Myeloproliferative Neoplasms

(2019) Cansu Cimen Bozkus et al.   Cancer Discovery

The Rationale for Immunotherapy in Myeloproliferative Neoplasms

(2019) Lucia Masarova et al.   Current Hematologic Malignancy Reports

Pegylated Interferon Alfa-2a for Polycythemia Vera or Essential Thrombocythemia Resistant or Intolerant to Hydroxyurea

(2019) Abdulraheem Yacoub et al.   BLOOD

Mutant calreticulin in myeloproliferative neoplasms

(2019) Joan How et al.   BLOOD

Tagraxofusp, the first CD123-targeted therapy and first targeted treatment for blastic plasmacytoid dendritic cell neoplasm

(2019) Minas P. Economides et al.   Expert Review of Clinical Pharmacology

Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial

(2019) Asra Ahmed et al.   Lancet Haematology

Phase I Clinical Trial of CK0801 (cord blood regulatory T cells) in Patients with Bone Marrow Failure Syndrome (BMF) Including Aplastic Anemia, Myelodysplasia and Myelofibrosis

(2019) Tapan M. Kadia et al.   BLOOD

Evaluation of Tagraxofusp (SL-401) Alone and in Combination with Ruxolitinib for the Treatment of Myeloproliferative Neoplasms

(2019) Aishwarya Krishnan et al.   BLOOD

Safety and Efficacy of Combined Ruxolitinib and Thalidomide in Patients with Myelofibrosis: A Phase II Study

(2019) Raajit K. Rampal et al.   BLOOD

Immunosuppression by Mutated Calreticulin Released from Malignant Cells

(2019) Peng Liu et al.   MOLECULAR CELL

Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy

(2018) Edit Porpaczy et al.   BLOOD

A Multi-center Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating Agent Failure

(2018) Amer M. Zeidan et al.   CLINICAL CANCER RESEARCH

Regulation of innate and adaptive antitumor immunity by IAP antagonists

(2018) Stephanie K Dougan et al.   Immunotherapy

Autocrine Tnf signaling favors malignant cells in myelofibrosis in a Tnfr2-dependent fashion

(2018) William L. Heaton et al.   LEUKEMIA

Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Non-randomized, Open-label, Phase 2 Study

(2018) Naval Daver et al.   Cancer Discovery

Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial

(2018) Uday R Popat et al.   Lancet Haematology

Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial

(2017) Srdan Verstovsek et al.   Journal of Hematology & Oncology

Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study

(2017) Francesco Passamonti et al.   LANCET ONCOLOGY

The calreticulin (CALR) exon 9 mutations are promising targets for cancer immune therapy

(2017) M O Holmström et al.   LEUKEMIA

Immunotherapy based approaches in myelofibrosis

(2017) Lucia Masarova et al.   Expert Review of Hematology

Smac mimetics synergize with immune checkpoint inhibitors to promote tumour immunity against glioblastoma

(2017) Shawn T. Beug et al.   Nature Communications

IAP Antagonists Enhance Cytokine Production from Mouse and Human iNKT Cells

(2017) Eleanor Clancy-Thompson et al.   Cancer Immunology Research

Targeting CD47: the achievements and concerns of current studies on cancer immunotherapy

(2017) Yuting Huang et al.   Journal of Thoracic Disease

Infectious complications in patients on treatment with Ruxolitinib: case report and review of the literature

(2017) Maria Veronica Dioverti et al.   Infectious Diseases

Bone marrow microvessel density and plasma angiogenic factors in myeloproliferative neoplasms: clinicopathological and molecular correlations

(2016) Danijela Lekovic et al.   ANNALS OF HEMATOLOGY

Homozygous calreticulin mutations in patients with myelofibrosis lead to acquired myeloperoxidase deficiency

(2016) A. P. A. Theocharides et al.   BLOOD

Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial

(2016) H. K. Al-Ali et al.   HAEMATOLOGICA

Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies

(2016) Marco Ruella et al.   JOURNAL OF CLINICAL INVESTIGATION

Role of neoplastic monocyte-derived fibrocytes in primary myelofibrosis

(2016) Srdan Verstovsek et al.   JOURNAL OF EXPERIMENTAL MEDICINE

A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence

(2016) A Tefferi et al.   LEUKEMIA

The JAK2V617F mutation is a target for specific T cells in the JAK2V617F-positive myeloproliferative neoplasms

(2016) M O Holmström et al.   LEUKEMIA

Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis

(2016) C N Harrison et al.   LEUKEMIA

Long-term results of a phase II trial of lenalidomide plus prednisone therapy for patients with myelofibrosis

(2016) Dai Chihara et al.   LEUKEMIA RESEARCH

IAP antagonists induce anti-tumor immunity in multiple myeloma

(2016) Marta Chesi et al.   NATURE MEDICINE

Ipilimumab for Patients with Relapse after Allogeneic Transplantation

(2016) Matthew S. Davids et al.   NEW ENGLAND JOURNAL OF MEDICINE

Antigen-specific immunotherapy for acute myeloid leukemia: where are we now, and where do we go from here?

(2016) Armin Rashidi et al.   Expert Review of Hematology

Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation

(2016) S. Elf et al.   Cancer Discovery

Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial

(2016) H. K. Al-Ali et al.   HAEMATOLOGICA

T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells

(2016) E. Zah et al.   Cancer Immunology Research

JAK inhibition induces silencing of T Helper cytokine secretion and a profound reduction in T regulatory cells

(2015) Clodagh Keohane et al.   BRITISH JOURNAL OF HAEMATOLOGY

T cells are functionally not impaired in AML: increased PD-1 expression is only seen at time of relapse and correlates with a shift towards the memory T cell compartment

(2015) Frauke M. Schnorfeil et al.   Journal of Hematology & Oncology

Mediators of Inflammation in Myeloproliferative Neoplasms: State of the Art

(2015) Sylvie Hermouet et al.   MEDIATORS OF INFLAMMATION

MPNs as Inflammatory Diseases: The Evidence, Consequences, and Perspectives

(2015) Hans Carl Hasselbalch et al.   MEDIATORS OF INFLAMMATION

Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition

(2015) Qiang Jeremy Wen et al.   NATURE MEDICINE

Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera

(2015) Alessandro M. Vannucchi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Neoantigens in cancer immunotherapy

(2015) T. N. Schumacher et al.   SCIENCE

Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis

(2014) R. Rampal et al.   BLOOD

Phase I Dose-Escalation Study of LCL161, an Oral Inhibitor of Apoptosis Proteins Inhibitor, in Patients With Advanced Solid Tumors

(2014) Jeffrey R. Infante et al.   JOURNAL OF CLINICAL ONCOLOGY

Synergistic Targeting of AML Stem/Progenitor Cells With IAP Antagonist Birinapant and Demethylating Agents

(2014) Bing Z. Carter et al.   JNCI-Journal of the National Cancer Institute

Therapeutic options for patients with polycythemia vera and essential thrombocythemia refractory/resistant to hydroxyurea

(2014) Matjaz Sever et al.   LEUKEMIA & LYMPHOMA

Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia

(2014) Naval Daver et al.   LEUKEMIA RESEARCH

Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon  -2a

(2013) A. Quintas-Cardama et al.   BLOOD

Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents

(2013) H Yang et al.   LEUKEMIA

Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2

(2013) J. Nangalia et al.   NEW ENGLAND JOURNAL OF MEDICINE

Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms

(2013) Thorsten Klampfl et al.   NEW ENGLAND JOURNAL OF MEDICINE

Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors

(2012) V. Gupta et al.   BLOOD

Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer?

(2012) H. C. Hasselbalch   BLOOD

Breakthroughs in myeloproliferative neoplasms

(2012) Santos   Hematology

A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

(2012) Srdan Verstovsek et al.   NEW ENGLAND JOURNAL OF MEDICINE

JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis

(2012) Claire Harrison et al.   NEW ENGLAND JOURNAL OF MEDICINE

Long-term outcome of pomalidomide therapy in myelofibrosis

(2011) Kebede H. Begna et al.   AMERICAN JOURNAL OF HEMATOLOGY

Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera

(2011) A. Alvarez-Larran et al.   BLOOD

TNF  facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms

(2011) A. G. Fleischman et al.   BLOOD

Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria

(2011) M. E. D. Flowers et al.   BLOOD

Control of Megakaryocyte Expansion and Bone Marrow Fibrosis by Lysyl Oxidase

(2011) Alexia Eliades et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Circulating Interleukin (IL)-8, IL-2R, IL-12, and IL-15 Levels Are Independently Prognostic in Primary Myelofibrosis: A Comprehensive Cytokine Profiling Study

(2011) Ayalew Tefferi et al.   JOURNAL OF CLINICAL ONCOLOGY

Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet

(2011) Tiziano Barbui et al.   JOURNAL OF CLINICAL ONCOLOGY

DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms

(2011) O Abdel-Wahab et al.   LEUKEMIA

Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia

(2011) David L. Porter et al.   NEW ENGLAND JOURNAL OF MEDICINE

International working group for myelofibrosis research and treatment response assessment and long-term follow-up of 50 myelofibrosis patients treated with thalidomide-prednisone based regimens

(2010) Prakash Thapaliya et al.   AMERICAN JOURNAL OF HEMATOLOGY

Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903

(2010) R. A. Mesa et al.   BLOOD

Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms

(2010) S. T. Oh et al.   BLOOD

Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia

(2010) Q. Zhou et al.   BLOOD

Antagonists of IAP proteins as cancer therapeutics

(2010) Jasmin N. Dynek et al.   CANCER LETTERS

Reprogrammed Foxp3+ Regulatory T Cells Provide Essential Help to Support Cross-presentation and CD8+ T Cell Priming in Naive Mice

(2010) Madhav D. Sharma et al.   IMMUNITY

Elevated frequencies of CD4+CD25+CD127lo regulatory T cells is associated to poor prognosis in patients with acute myeloid leukemia

(2010) Zhang Shenghui et al.   INTERNATIONAL JOURNAL OF CANCER

IAP inhibitors enhance co-stimulation to promote tumor immunity

(2010) Michael Dougan et al.   JOURNAL OF EXPERIMENTAL MEDICINE

IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis

(2010) A Tefferi et al.   LEUKEMIA

Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders

(2010) Thomas Ernst et al.   NATURE GENETICS

Allogeneic Stem Cell Transplantation for Myelofibrosis with Leukemic Transformation

(2009) Stefan O. Ciurea et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Peripheral blood T cells in acute myeloid leukemia (AML) patients at diagnosis have abnormal phenotype and genotype and form defective immune synapses with AML blasts

(2009) R. Le Dieu et al.   BLOOD

CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis

(2009) Siddhartha Jaiswal et al.   CELL

CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells

(2009) Ravindra Majeti et al.   CELL

Increased Frequency and Suppression by Regulatory T Cells in Patients with Acute Myelogenous Leukemia

(2009) M. J. Szczepanski et al.   CLINICAL CANCER RESEARCH

Pomalidomide Is Active in the Treatment of Anemia Associated With Myelofibrosis

(2009) Ayalew Tefferi et al.   JOURNAL OF CLINICAL ONCOLOGY

Pegylated Interferon Alfa-2a Yields High Rates of Hematologic and Molecular Response in Patients With Advanced Essential Thrombocythemia and Polycythemia Vera

(2009) Alfonso Quintás-Cardama et al.   JOURNAL OF CLINICAL ONCOLOGY

Mutations of ASXL1 gene in myeloproliferative neoplasms

(2009) N Carbuccia et al.   LEUKEMIA

Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms

(2009) Masashi Sanada et al.   NATURE

Mutation inTET2in Myeloid Cancers

(2009) François Delhommeau et al.   NEW ENGLAND JOURNAL OF MEDICINE

Myeloproliferative disorders

(2008) R. L. Levine et al.   BLOOD

First thalidomide clinical trial in multiple myeloma: a decade

(2008) F. van Rhee et al.   BLOOD

Phase I Safety and Pharmacokinetic Study of CT-011, a Humanized Antibody Interacting with PD-1, in Patients with Advanced Hematologic Malignancies

(2008) R. Berger et al.   CLINICAL CANCER RESEARCH

Interferon-α therapy in bcr-abl-negative myeloproliferative neoplasms

(2008) J-J Kiladjian et al.   LEUKEMIA